University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration. As part of this collaboration, M.D. Anderson has joined an ongoing Phase I/II clinical trial of SL-401 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

"We are pleased to be involved with Stemline and its innovative programs targeting cancer stem cells," said Hagop Kantarjian, MD, Chairman of the Department of Leukemia at M.D. Anderson. "This clinical trial provides a new option for our patients with AML and MDS."

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have M.D. Anderson, a world class institution and leader in oncology, join the ongoing Phase I/II study in AML and MDS for SL-401 and work with us on additional programs. This is an exciting time for the company as we expand our clinical program, advance our diverse pipeline, and continue to build out our proprietary platforms."